Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;197(2):377-385.
doi: 10.1007/s10549-022-06807-w. Epub 2022 Nov 23.

Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry

Samia Kada Mohammed  1 , Tienhan Sandrine Dabakuyo Yonli  2   3 , Isabelle Desmoulins  4 , Ariane Manguem Kamga  2   3 , Clémentine Jankowski  5 , Marie-Martine Padeano  5 , Catherine Loustalot  5 , Hélène Costaz  5 , Sylvain Causeret  5 , Karine Peignaux  6 , Magali Rouffiac  6 , Charles Coutant  5   7 , Laurent Arnould  8 , Sylvain Ladoire  9   10   11
Affiliations

Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry

Samia Kada Mohammed et al. Breast Cancer Res Treat. 2023 Jan.

Abstract

Purpose: The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC.

Methods: We designed a retrospective study using data from the specialized Côte d'Or Breast and Gynecological cancer registry, between 1998 and 2015, to compare outcomes between 3 matched groups of patients with localized IBC: patients with LIR following CIS (CIS-LIR), patients with de novo IBC (de novo IBC), and patients with LIR following a first IBC (IBC-LIR). Distant relapse-free (D-RFS), overall survival (OS), clinical, and treatment features between the 3 groups were studied.

Results: Among 8186 women initially diagnosed with IBC during our study period, we retrieved and matched 49 CIS-LIR to 49 IBC, and 46 IBC-LIR patients. At diagnosis, IBC/LIR in the 3 groups were mainly stage I, grade II, estrogen receptor-positive, and HER2 negative. Metastatic diseases at diagnosis were higher in CIS-LIR group. A majority of patients received adjuvant systemic treatment, with no statistically significant differences between the 3 groups. There was no significant difference between the 3 groups in terms of OS or D-RFS.

Conclusion: LIR after CIS does not appear to impact per se on survival of IBC.

Keywords: Breast cancer; DCIS; Ductal carcinoma in situ; Local invasive recurrence; Survival; Systemic adjuvant therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival curves for distant relapse-free survival and overall survival for the 3 groups of patients. A Distant relapse-free survival, B overall survival
See this image and copyright information in PMC

References

    1. Cutuli B, Lemanski C, De Lafontan B, Chauvet M-P, De Lara CT, Mege A, et al. Ductal carcinoma in situ: a french national survey. analysis of 2125 patients. Clin Breast Cancer. 2020;20(2):e164–e172. doi: 10.1016/j.clbc.2019.08.002. - DOI - PubMed
    1. Lee LA, Silverstein MJ, Chung CT, Macdonald H, Sanghavi P, Epstein M, et al. Breast cancer–specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. Am J Surg. 2006;192(4):416–419. doi: 10.1016/j.amjsurg.2006.06.005. - DOI - PubMed
    1. Donker M, Litière S, Werutsky G, Julien J-P, Fentiman IS, Agresti R, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase iii trial. J Clin Oncol. 2013;31(32):4054–4059. doi: 10.1200/JCO.2013.49.5077. - DOI - PubMed
    1. Lagios MD. Duct carcinoma in situ: pathology and treatment. Surg Clin North Am. 1990;70(4):853–871. doi: 10.1016/S0039-6109(16)45185-6. - DOI - PubMed
    1. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer. 1995;31(9):1425–1427. doi: 10.1016/0959-8049(95)00283-O. - DOI - PubMed

MeSH terms